Important step towards a potential new Lewy body dementia treatment
Hope for the first drug licensed in the UK specifically for Lewy body dementia has received a significant boost after neflamapimod was awarded a UK
It is Lewy body Society’s mission to fund clinical research, understand the causes of Lewy body dementia, and advance its diagnosis and treatment. We have funded ground-breaking projects and worked with top UK universities since 2007.
The Lewy Body Society is an NIHR RDN Non-commercial Partner. This means the studies that we fund may be eligible to access the NIHR Study Support Service which is provided by the NIHR Research Delivery Network within the NHS, and the wider public health and social care environment, across England.
To ensure we fund the best quality research into Lewy body dementia we have a thorough peer review process which follows guidelines set out by the Association of Medical Research Charities.
Our Specialist Advisory Committee ensures we make objective funding decisions that comply with our research strategy.
These 15 UK-based experts review all applications for our grant funding, along with input from expert reviewers from across the world.
Hope for the first drug licensed in the UK specifically for Lewy body dementia has received a significant boost after neflamapimod was awarded a UK
Better understanding of Lewy body dementia only happens through research. For 20 years, the Lewy Body Society has helped make that possible by funding studies
The Lewy Body Society has invested £3.4m in research to improve diagnosis, care and treatment over the past 20 years. During this current £500,000 20th-anniversary